Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,639 | 277 | 1,314 |
| Samples | 1,427 | 236 | 1,174 |
| Peptides | 1,033 | 158 | 879 |
Function
EP300 · EP300 lysine acetyltransferase
This gene encodes the adenovirus E1A-associated cellular p300 transcriptional co-activator protein. It functions as histone acetyltransferase that regulates transcription via chromatin remodeling and is important in the processes of cell proliferation and differentiation. It mediates cAMP-gene regulation by binding specifically to phosphorylated CREB protein. This gene has also been identified as a co-activator of HIF1A (hypoxia-inducible factor 1 alpha), and thus plays a role in the stimulation of hypoxia-induced genes such as VEGF. Defects in this gene are a cause of Rubinstein-Taybi syndrome and may also play a role in epithelial cancer. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000263253 | Q09472 | 1,638 | 1,032 |
| ENST00000715703 | - | 1 | 1 |
Gene Properties
Recurrent Mutations
All 1032 amino-acid changes on canonical ENST00000263253 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in EP300 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in EP300 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 12/40 30% | 0/0 0% |
| Chronic Myelogenous Leukemia | 4/25 16% | 0/0 0% |
| Oral Cavity Carcinoma | 6/54 11% | 0/0 0% |
| Endometrial Carcinoma | 16/42 38% | 41/612 7% |
| Acute Monocytic Leukemia | 0/1 0% | 2/25 8% |
| T-Cell Non-Hodgkins Lymphoma | 2/26 8% | 0/0 0% |
| Bladder Carcinoma | 6/58 10% | 69/956 7% |
| Hodgkins Lymphoma | 6/16 38% | 4/122 3% |
| Glioblastoma | 7/98 7% | 0/0 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 9/133 7% |
| Esophageal Squamous Cell Carcinoma | 8/51 16% | 167/2550 7% |
| Cervical Carcinoma | 3/35 9% | 24/422 6% |
| Other Solid Cancers | 4/94 4% | 84/1515 6% |
| Melanoma | 12/210 6% | 97/1899 5% |
| Neuroendocrine Tumour | 19/154 12% | 17/577 3% |
| Squamous Cell Lung Carcinoma | 9/57 16% | 32/810 4% |
| Colorectal Carcinoma | 31/143 22% | 121/3239 4% |
| Small Cell Lung Carcinoma | 0/9 0% | 33/752 4% |
| Head and Neck Carcinoma | 8/85 9% | 60/1574 4% |
| Gastric Carcinoma | 7/74 9% | 53/1809 3% |
| Germ Cell Tumour | 0/25 0% | 6/169 4% |
| Other Sarcomas | 6/69 9% | 17/699 2% |
| Non-Small Cell Lung Carcinoma | 11/304 4% | 36/1390 3% |
| Unknown | 0/10 0% | 1/29 3% |
| Hepatocellular Carcinoma | 5/46 11% | 48/2210 2% |
| Esophageal Carcinoma | 0/23 0% | 18/769 2% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| B-Cell Non-Hodgkins Lymphoma | 8/88 9% | 46/2534 2% |
| Osteosarcoma | 2/45 4% | 2/166 1% |
| Burkitts Lymphoma | 3/32 9% | 1/196 1% |
Mutation Distribution
Where EP300 is mutated · all tissues, split by cell line vs tissue
How many mutations in EP300 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,639 mutations in EP300
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|